Avoid common mistakes on your manuscript.
Erratum to: Ann Surg Oncol (2011) DOI 10.1245/s10434-011-2190-5
In the original article, Fig. 1 contained an error. The bottom left box of the figure should have said “Continued Imatinib 600 mg/day for 24 months” not “Continued Imatinib 600 mg/day for 24 hours.”
Schematic representation of the trial. SD stable disease, PR partial response, PD progressive disease
The figure is reprinted here correctly.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1245/s10434-011-2190-5.
Rights and permissions
About this article
Cite this article
Wang, D., Zhang, Q., Blanke, C.D. et al. Erratum to: Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol 19, 2420 (2012). https://doi.org/10.1245/s10434-012-2228-3
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-012-2228-3